Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026
Combine with aerobic exercise to promote fat dairies
Er ist kein Appetitzgler und keine Abnehmspritze
[299] conducted a Phase 2B, double-blind, RCT to evaluate the efficacy, safety and microbiome alterations associated with two dose levels of SER-287 (microbiome therapy containing a consortium of live bacterial spores), after pre-treatment with vancomycin, in active mild-to-moderate UC
GLP-1RA promotes the secretion of GLP-1 by intestinal L cells while inhibiting the secretion of glucagon by alpha cells, forming a positive feedback regulation of the "gut pancreas" axis
Peter Attia draws on the latest science to deliver innovative nutritional interventions, techniques for optimizing exercise and sleep, and tools for addressing emotional and mental health